Background Narrowband ultraviolet B (NB-UVB) treatment for psoriasis is considered expensive. However, existing data are based on estimates and do not consider indirect cost savings. Objectives To define the actual costs of NB-UVB incurred by the service provider, as well as treatment-associated cost savings. Methods We performed data linkage of (i) comprehensive treatment records and (ii) prescribing data for all NB-UVB treatment episodes spanning 6 years in a population of 420 000. We minimized data fluctuation by compiling data from four independent treatment sites, and using drug prescriptions unrelated to psoriasis as a negative control. Results National Health Service Tayside spent an average of £257 per NB-UVB treatment course (mean 257 AE 63, range 150-286, across four independent treatment sites), contrasting sharply with the estimate of £1882 used by the U.K. National Institute for Health and Care Excellence. The cost of topical treatments averaged £128 per patient in the 12 months prior to NB-UVB, accounting for 42% of the overall drug costs incurred by these patients. This was reduced by 40% to £53 per patient over the 12-month period following NB-UVB treatment, while psoriasis-unrelated drug prescription remained unchanged, suggesting disease-specific effects of NB-UVB. The data were not due to site-specific factors, as confirmed by highly similar results observed between treatment sites operated by distinct staff. Finally, we detail all staff hours directly and indirectly involved in treatment, allowing direct translation of cost into other healthcare systems. Conclusions NB-UVB is a low-cost treatment; cost figures currently used in health technology appraisals are an overestimate based on the data presented here. Creating or extending access to NB-UVB is likely to offer additional savings by delaying or avoiding costly third-line treatments for many patients.
Narrowband ultraviolet B (NB-UVB) treatment has been shown to be effective in psoriasis in numerous clinical trials, [1] [2] [3] [4] [5] and represents a cornerstone of treatment. However, the treatment has a reputation of being costly and difficult to implement. This perception is reflected in treatment guidelines, such as the most recently published British Association of Dermatologists (BAD) guidelines, which fail even to include NB-UVB in the biological drug treatment pathway (recommendation R4). 6 Defining the actual full cost of a nondrug-based treatment is notoriously difficult. Thus, available data on the economics of UVB rely on assumptions on factors such as staff-related or estate cost, 7, 8 rather than actual financial turnover. This is chiefly due to the difficulties in obtaining high-quality data. Rather than analysing actually incurred cost, studies tend to focus on derived constructs such as quality-adjusted life-years, and not on precise delineation of actual expenditure (e.g. summarily derived phototherapy costs from National Tariffs). 9 In addition, to the best of our knowledge, no published reports have considered the financial impact of NB-UVB-associated cost savings by potentially reduced need for concomitant topical treatment following NB-UVB therapy. This lack of data is most likely due to the difficulties in retrieving comprehensive treatment records.
As detailed previously, we have electronic access to the complete records of all medical prescriptions filled for a population of 420 000 across Tayside, Perthshire and North East Fife in Scotland. 10 The population as such is marked by both low demographic mobility and complete service provision through a single healthcare provider -National Health Service (NHS) Tayside. In addition, phototherapy for the entire population is provided by one single department, dispensed at four separate treatment sites, and clinical treatment outcomes are prospectively recorded. We have most recently interrogated this comprehensive dataset to define the efficacy of NB-UVB treatment for psoriasis under real-world conditions. 11 These data showed that NB-UVB treatment is highly effective and leads to a significant reduction in topical cream treatments prescribed for psoriasis.
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Here we apply our uniquely comprehensive set of data to compile the expenses incurred by a healthcare provider for the treatment of psoriasis with NB-UVB based on actual costs, taking into account savings achieved through reduced need for topical psoriasis treatment. Our data represent the actual cost incurred by the provider for all treatment episodes over a period of 6 years, including the magnitude of variability associated with distinct staff operating treatment at separate sites, as well as fluctuations occurring over several years. Strikingly, we find that NHS Tayside achieved significant cost savings in drug dispensing in patients with psoriasis treated with NB-UVB. In order to make our data generally applicable, we also detail staff hours allocated to NB-UVB treatment provision, thereby making the local net cost transferable to other healthcare constellations. As treatment with NB-UVB phototherapy can reduce the requirement and frequency of costly third-line treatments like biologics, our data suggest that investment in access to NB-UVB treatment represents a viable cost-saving measure for healthcare providers.
Patients and methods
All data generated in this study were obtained in accordance with the Declaration of Helsinki and in compliance with local governance approval regulations (Caldicot number CSAppJF2101). The use of local Tayside phototherapy data was approved by the National Managed Clinical Network for Phototherapy, Photonet. This is an observational cohort study, carried out in accordance with the STROBE checklist 12 (see Appendix S1 in the Supporting Information for the full statement). All methods pertaining to ascertainment of the patient cohort, cohort refinement, cohort validation, prescribing data collection and refinement, quantification of psoriasis treatments, extraction of psoriasis-specific drug prescribing, data linkage, definition of NB-UVB treatment episodes, and study design have been described in detail. 11 Statistical tests, as well as the statistical analyses shown in the figures and tables, were performed using StatPlus software (AnalystSoft, Walnut, CA, U.S.A.). Data for calculation of prescriptions charges were accessed from the prescribing reports provided by Information Services Division Scotland. 13 Full details are provided in Appendix S1
(see Supporting Information).
Costs incurred due to NB-UVB were calculated. Details of all staff costs are shown in the Supporting Information as follows. Table S1 contains the number of treatment courses administered at each site throughout the observation period. Table S2 details the precise staff costs for all job roles involved in treatment. Table S3 lists estates cost, and Table S4 shows the overall treatment cost based on all data. Table S5 lists the summary of staff hours incurred, allowing calculation of costs for other economic regions based on local staff cost. Table S6 details the data used to derive the summary data in Table S5 .
Results

The cost of topical psoriasis treatment
We collected data from all consecutive patients registered on the PhotoSys database, limiting analysis to the initial first-ever NB-UVB treatment administered for psoriasis, as described in detail previously. 11 The patient cohort represents a significant fraction of all patients referred for specialist-supervised psoriasis treatment from primary care (n = 1749). As such, this cohort represents a longitudinal sample of patients with moderate-to-severe psoriasis. The fact that they had been referred to secondary care implies that the managing general practitioner assessed control of their disease as inadequate. In Tayside, primary care of psoriasis is limited to the use of topical treatment. Thus, the majority of patients in the cohort are likely to have received the maximal extent of topical treatment available at the time of referral. Table 1 lists the actual cost incurred by the healthcare provider. The combined prescription of all topical treatments between January 2008 and January 2015 amounted to £128 per patient, or £35 713 per year. Of note, despite similar numbers of prescriptions made for steroid-containing creams and 'psoriasis-specific' creams, the latter account for a much higher cost per treatment (£19 vs. £92 per patient, respectively). In patients with psoriasis, treatment of their psoriasis amounts to 42% of all costs spent on prescription drugs (sum of steroids, psoriasis-specific creams and emollient topicals), as shown in Figure 1 .
We also analysed the spread and variation of the treatment cost incurred per patient. As shown in Figure 2 (top), the cost per patient was low overall, while increasingly small subgroups of patients generated increasingly high cost. This is also shown in a box plot representation of the data ( Fig. 2 ; bottom), which shows that the median cost (yellow) was much lower than the average (mean) cost (red), with very few patients representing extreme outliers (green). This is summarized in Table 2 .
We interrogated the data for evidence of other factors potentially influencing psoriasis-associated drug expenditure, but did not observe any significant differences between patients receiving treatment at different locations. There was also no effect on cost by patient sex or age at first NB-UVB treatment (age at diagnosis was not available).
The impact of narrowband ultraviolet B on the cost of prescription drugs
We next analysed the cost incurred by NHS Tayside before and after an initial NB-UVB treatment course in the 12-month intervals prior to and after treatment (this was set to begin 4 months after initiation of NB-UVB treatment, as described in detail previously). 11 As shown in Figure 3 , there was a statistically significant decrease in the cost of steroid creams and psoriasis-specific topical treatments, both overall annually and per patient spending. There was no statistically significant change in prescription costs for any of three independent prescription classes (hypertension, depression, and all other prescriptions items combined; Fig. 3 ). Moreover, we have previously shown that the reduction in psoriasis-related prescriptions is not randomly spread among all patients but is more pronounced in those patients exhibiting a better treatment outcome of NB-UVB. 11 Therefore, several lines of evidence suggest that the observed changes in drug prescribing -and hence cost -were unlikely to be merely associated by chance with NB-UVB treatment, but were much more likely directly caused by the treatment. Table 3 details savings made following NB-UVB treatment for each of the topical treatment drug classes. The overall savings amounted to £50Á74 per patient, corresponding to approximately 40% reduction in per-patient prescription drug costs. On an individual level, the actual change in expenditure varied widely between patients. As shown in Figure 4 , while most patients achieved cost savings for both steroids and psoriasis-specific topicals, there was a significant minority exhibiting an increase in drug expenditure. As expected, and detailed previously, 11 the number of prescriptions was most markedly reduced in patients who had been recorded as 'clear' or with 'minimal residual disease' following NB-UVB treatment, further confirming that net reduction of cost was due to the effect of NB-UVB treatment.
In addition to the drug cost, the NHS incurs a cost for each filled prescription. According to the Information Services Division Scotland, these charges are approximately £0Á70 per prescription (Appendix S1; see Supporting Information). We Table 1 ). H1, antihistamines; Depr, antidepressant drugs; HTN, antihypertensives. The definition 'Pso-creams' refers to topical treatments only prescribable for psoriasis in the British National Formulary (BNF code 13.5.2) and comprises calcipotriol, calcipotriol with betamethasone, calcitriol, coal tar products, dithranol, salicylic acid compounds, tacalcitol and tazarotene.
therefore quantified the number of prescriptions made for each of the topical treatment drug classes. As shown in Table 4 , there was a significant reduction in prescriptions, amounting to overall savings of £2Á48 per patient. Therefore, each NB-UVB treatment course in Tayside is associated with net savings of £53Á22 in topical treatment costs.
Staff-related and staff-unrelated cost of narrowband ultraviolet B treatment
The cost incurred by NB-UVB treatment involves a number of items including both staff-related and non-staff-related costs. We identified each of these cost components for each of the individual treatment sites analysed ( Table 5) . As the cost per treatment critically depends on the actual numbers dispensed we also analysed the fluctuation of annual treatment number over the entire observation window (Table S1 ; see Supporting Information) and calculated the average cost per treatment by using the average, thereby safeguarding the data against shortterm fluctuations. We observed a very low overall variability in treatment number over the entire observational window ( Table 5 ). The staff costs listed in Table 5 are not estimates but rather represent the actual staff hours allocated to the various aspects of NB-UVB administration at each of the four sites, as shown in detail in Table S2 (see Supporting Information).
The average costs across all sites, both absolute and by relative contribution, are shown in Figure 5 . As expected, the costliest component is staff time, accounting for 92% of the cost. 'Nurse time' constitutes the largest share (84% of the total cost; for details see Table S4 in the Supporting Information, boxed 'relative contribution'), where this item includes treatment administration, documentation, data entry, letter dictation and continuous professional training. Furthermore, the staff cost shown in Table 5 includes both employer pension and National Insurance contributions (details in Table S2 ; see Supporting Information).
Variability of treatment cost across treatment sites
The cost of any highly staff-dependent medical treatment could be significantly modified by site-specific factors nonexistent in other centres, which could render the resulting data less informative. As we had access to site-specific data, we therefore also analysed the variability in cost between separate centres run by distinct staff (Table 5 ). We did not observe an overall trend between large (Dundee), medium (Perth) and small (St Andrews, Stracathro) centres. Rather, variation in cost appeared to be related primarily to the number of Pso-specific topicals Emollients
The distribution of cost for topical psoriasis treatments in primary care in Scotland. Top: histogram plots for all patients (n = 1749) incurring annual costs, up to the threshold amounts given in pounds on the x-axis for each of the drug classes indicated. Bottom: box plots showing percentiles, median, average costs and distribution of outliers, as indicated in the colour-coded lines. Pso-specific, psoriasis-specific. session generates a cost of £8Á50.
Allocation of staff hours to narrowband ultraviolet B treatment
As the cost for phototherapy is highly salary dependent, we also listed the actual staff hours required to dispense treatment in an effort to render our data transferable to other economic contexts, as long as local salary scales are known (summarized in Table S5 and detailed in Table S6 ; see Supporting Information). One important aspect of this is that treatment is not carried out by single members of staff but is spread into job-plan components of various staff. For example, even at the smallest treatment site (Stracathro), primary treatment is shared between five local staff, each contributing roughly 20% of their job plan. This set-up may contribute to the overall The figure shows the total cost incurred by National Health Service Tayside, expressed in pounds before and after NB-UVB treatment. Top: cost per annum for all patients, Bottom: annual cost per patient. *P < 0Á01 in a paired t-test. Depr, antidepressant drugs; HTN, antihypertensive drugs; Pso-topicals, psoriasis-specific topicals. Annual savings are calculated for 12 months out of the total 75-month observational window. Within the entire cohort (n = 1749), this number is equivalent to savings made for 280 patients. resilience of the service, leading to overall low fluctuation in treatment numbers, as detailed above. One complete NB-UVB course required a total of 0Á45 AE 0Á14 staff hours, including direct and indirect support roles. By substituting local salary scales, these data allow calculation of the analogous cost likely to be incurred by service providers operating in distinct economical contexts.
Discussion
On average, NHS Tayside spent £257 for each NB-UVB treatment course administered for psoriasis (including all staff overheads) and saved £53. The resulting net average cost of £204 makes this obviously a very economical treatment option. In more general terms, one complete NB-UVB course required an average of 0Á45 AE 0Á14 staff hours. These figures represent averages across four separate treatment sites spanning 6 years, thereby eliminating any spurious fluctuations over time or bias inherent in local factors specific to individual treatment sites. As such, the real cost of NB-UVB contrasts sharply with the previous U.K. National Institute for Health and Care Excellence (NICE) assignment of £1882 per NB-UVB treatment course.
14 Notably, the actual net expenditure reported here is less than even that of methotrexate cited by NICE based on the British National Formulary drug tariff (£404 per annum).
14 Our data contrast with previously reported studies. One realworld study from Finland assigned a cost of €755 for a course of NB-UVB, with an average of 14 sessions per course. 15 However, it is not clear how the price charge of €32 per session cited therein related to the cumulative price. In addition, these authors included external items (e.g. lab cost) and arbitrarily levied NB-UVB charges that are not inherent treatment costs but rather form part of an overall profitable pricing structure. Another Finnish-based real-world study from 2009 assigned €39 per annum to methotrexate and €351 per annum to acitretin, but did not quantify NB-UVB cost, despite stating that this was applied to 36% of patients. 16 One recent review based in the U.S.A. assigned a direct treatment cost of office-based NB-UVB as ranging between $1414 and $6676 per course based on three cited studies. However, these figures were compiled based on estimates, rather than actual costs, and did not attempt to explain the huge variability in the cited studies. 17 Again, the notably The numbers shown are the absolute prescription fees incurred by National Health Service Tayside as remuneration for pharmacies for filling prescriptions made out for all patients with psoriasis (n = 1749) in the 12-month intervals before and after NB-UVB treatment, calculated for treatments occurring within a single year or per patient. The data show the cost incurred per treatment course rounded to the nearest pound (£) (see Table S4 ). b Average AE SD between 2010 and 2015. One course consists of an average AE SD of 30 AE 10 treatment sessions, with minimal variation between the four different centres, as previously shown. 11 c For salary components, including indirect cost (pension and National Insurance cost), see Table S2 . d Cost includes staff hours allocated to treatment administration, documentation, data entry, letter dictation and continuous professional training. The data shown are derived from the salary scales detailed in Table S2 for each of the centres.
e Secretarial support; the numbers shown cover staff hours allocated to typing and appointment booking. f Includes staff hours by both consultants and registrars allocated to phototherapy as per the job plan (see Table S6 ). g Based on a purchasing price of £1603 as directly incurred by NHS Tayside in 2015 for one NB-UVB cabinet including depreciation, average lifetime and replacement kit (bulbs). Cost of two units used for the Dundee site (Ninewells Hospital). h Includes maintenance and lamp calibration, as provided by Medical Physics. i Based on the published cost for cleaning, property maintenance, energy and rates per m 2 in NHS Tayside (for details see Table S3 ). For Tables S2, S3, S4, S6, see Supporting Information. higher cost, aside from the locally varying cost of labour, likely reflects costs accruing within a for-profit business model. Even in England, which still has a national health service, services such as phototherapy are not evaluated on the basis of real cost but are assigned tariffs. For phototherapy, the assumed tariff is £74 per session for patients aged > 13 years and £86 for those aged ≤ 12 years, 18 which is in striking contrast with the actual cost (£8Á50 per session; see above). Clearly, this would constitute a disincentive to provide treatment. Numerous other health economic studies focusing primarily on more expensive biologics have assigned a cost to NB-UVB as a comparator treatment. However, these studies generally focus on 'cost per PASI 75' (≥ 75% improvement in Psoriasis Area and Severity Index), using data from controlled trials rather than real-world direct cost, as detailed here. Thus, the data reported here, to the best of our knowledge, represent the most comprehensive direct measurement of the actual cost accrued for NB-UVB treatment to date.
Importantly, it should be noted that the cost of NB-UVB we describe here does not come at the price of reduced efficacy. Rather, we recently documented that NB-UVB is highly effective in psoriasis under real-world conditions. 11 Taking together the available evidence, NB-UVB is not only effective but is by far the most economical treatment option for psoriasis inadequately controlled with topical treatments, perhaps with the exception of methotrexate. However, in contrast to NB-UVB, methotrexate is associated with a number of adverse events, as we have recently quantified both in clinical trials and under real-world conditions. 10, 19 In conjunction with our analysis of the efficacy of NB-UVB, 11 our data therefore dispel a widely held implicit notion that NB-UVB is expensive (as reflected in the NICE statement cited above) and ineffective. As such, from the perspective of healthcare provision, extending access to and widening the implementation of NB-UVB deserves serious consideration.
The present study has a number of obvious limitations. Firstly, we included only initial NB-UVB courses and only those administered for psoriasis, as dictated by the study design. 11 Secondly, we did not consider other phototherapy applications, especially psoralen-ultraviolet A (PUVA), which are commonly offered by the same centres. Thirdly, we did not consider nonprovider costs by patients (or employers), including travel and absence from work (for indicative data on the latter see Koek et al.) .
9 Such costs can be reduced by provision of a comprehensive phototherapy service including home phototherapy 20, 21 and patient self-administration phototherapy 22 for those who cannot readily attend the hospital units (which must have adequate opening hours). Fourthly, we did not perform health economic modelling, such as modelling of treatment outcomes to derive costs related to quality-adjusted life-years. Finally, our analysis provides direct costs only for the U.K. NHS-based hospital context. However, we have provided detailed functional staff-hour allocation, which we hope will enable readers to translate the cost into other salary contexts (see below).
In the course of this study we also defined the actual cost associated with topical treatment for psoriasis on a population level. Thus, in Tayside, Scotland, treatment with creams for psoriasis accounts for 42% of the total cost incurred by patients with disease of sufficient severity to warrant referral to secondary care (Fig. 1) . The actual annual cost of these creams (£128, Table 1 ) is much lower than the NICE estimate for the U.K., 14 possibly reflecting the previously noted relative undertreatment of psoriasis under real-world conditions. By way of comparison, the data in Table 1 show that the cost incurred per patient for psoriasis drugs is commensurate to the per-patient treatment cost for hypertension in patients requiring three different hypertensive agents and a nurse specialist review. 23 Therefore, it is remarkable that this cost is reduced by an average of approximately 40% over the 12-month interval following NB-UVB treatment. To the best of our knowledge, NB-UVB is the only psoriasis treatment confirmed to incur directly proven significant net savings in topical treatment cost to date. Of note, our data show a non-Gaussian distribution of cost (Fig. 2) , which should inform future model development. Moreover, the cost of topical treatment for psoriasis, as detailed here, represents a comprehensive real-world population sample, as opposed to a treatment cohort subject to selection and reporting bias, as discussed previously.
11 Therefore, these data (Table 2) should prove valuable to regulating bodies, such as NICE, when estimating cost-effectiveness for alternative treatments. The actual cost of NB-UVB in everyday practice is likely to be even lower than reported here for three reasons. Firstly, the average efficacy, and thus indirect savings in topical creams, are likely even more pronounced in subsequent NB-UVB courses, as patients experiencing no or limited benefit in the initial treatment episode are less likely to undergo repeat treatment, thereby introducing a bias towards greater relative efficacy. Secondly, the numbers of outpatient visits and general practitioner reviews are likely also reduced. Thirdly, administration of third-line systemic or biological treatments will be delayed, or even avoided, in some patients, adding further savings.
Although considered here for psoriasis, NB-UVB is also efficacious in other conditions. For example, oral systemic treatments for pruritic dermatoses often prove ineffective in establishing symptomatic control. Our data illustrate that antihistamine consumption is reduced following administration of NB-UVB, even in patients with psoriasis, 11 confirming the widespread observation that NB-UVB is effective to control pruritus. 24, 25 Other common conditions, notably eczema 26, 27 and urticaria, 28 also show good response to this treatment, thereby adding to indirect net savings by creating synergy on staff and equipment cost. How much would it cost to establish new access to NB-UVB locally? The data provided in Tables S5 and S6 (see Sup- porting Information) allow calculation of the cost faced by providers when setting up or extending NB-UVB treatment facilities. For example, the small treatment centre in Stracathro allocates 33 h per week, distributed to 20% of a 40-h work week among four nurses, to run the service, thus allowing sufficient cross-cover for staff absence. Consultant and other medical supervision is allocated at 1 h per week; equipment, maintenance and estate costs need to be added but have less cost implication.
Using the NHS salary costs (Table S2 ; see Supporting Information) the entire staff cost package, including pension and insurance contribution, for this site amounts to £30 750 per year, in return for a total of 152 NB-UVB and 81 PUVA treatment courses. The staff cost can be readily adapted to local salary scales using the staff hour breakdown given in Table S6 (see Supporting Information). Even in healthcare systems where the additional savings gained through reduced drug treatments (£53 per treatment) are not allocated to the NB-UVB service provider, and allowing for added cost for implementation, both set-up and running costs are recouped by delaying the need to prescribe biological treatment by 1 year in as few as three patients (Scottish Medicines Consortium cost template). 29 It is also worth pointing out that Tayside, Scotland, is a very rural clinical setting, requiring patients to travel comparatively large distances in order to attend for treatment, with relatively large impact on loss of work hours. It is likely that patient acceptance and compliance will be even easier to achieve in urban areas. Given the added benefits of this service, our data suggest that implementation of an NB-UVB service not only offers effective treatment, but may be also highly attractive in economic terms for providers.
The efficacy and cost-effectiveness of NB-UVB treatment are difficult to reconcile with its position in various current psoriasis treatment guidelines. Thus, the current BAD guidelines do not even consider NB-UVB in the pathway to biologics treatment. 6 Similarly, many guidelines consider NB-UVB as a treatment option, but not one that should be actively encouraged. In these cases, safety is cited as a reason to discourage treatment. Thus, the updated Canadian guidelines state that 'it has not been established whether NB-UVB is carcinogenic in humans; however, speculation based on nonclinical data suggests that NB-UVB could be more carcinogenic than natural [. obviously drug toxicity is known only for PUVA and is entirely absent in NB-UVB. The current guidelines of the U.S. American Academy of Dermatology also do not even suggest that NB-UVB ought to be actively considered before moving to systemic treatments. Likewise, the U.S. National Psoriasis Foundation actively opposes any effort to apply cost-effective treatments ahead of more expensive alternatives (called 'step therapy'), lobbying actively for legislation to ban this approach. Clearly, NB-UVB poses significant obstacles, not measured here, including nonprovider costs such as travel, absence from work, time commitment and scheduling difficulties. These issues will limit practical use in many cases. These limitations notwithstanding, treatment recommendations on psoriasis in many countries do not reflect analysis of the efficacy of NB-UVB, 11 or its costeffectiveness. The data presented here provide a rationale to review such guidelines.
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